Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LEGN Legend Biotech	$42.13 +6.0%	$33.61	$27.34 ▼ $60.87	$7.30B	0.19	1.37 million shs	3.29 million shs
RDY Dr. Reddy's Laboratories	$14.70 +0.6%	$14.89	$12.26 ▼ $16.89	$12.20B	0.33	1.51 million shs	1.21 million shs
SRPT Sarepta Therapeutics	$21.97 +19.5%	$28.86	$16.88 ▼ $150.48	$1.81B	0.45	2.39 million shs	19.70 million shs
VRNA Verona Pharma PLC American Depositary Share	$104.78 +0.0%	$85.95	$18.51 ▼ $104.99	$8.92B	0.24	1.72 million shs	4.89 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LEGN Legend Biotech	+0.40%	+0.73%	+10.91%	+21.19%	-28.89%
RDY Dr. Reddy's Laboratories	+0.53%	-0.80%	-6.75%	+6.91%	-6.71%
SRPT Sarepta Therapeutics	+0.93%	-5.11%	-12.23%	-65.83%	-87.66%
VRNA Verona Pharma PLC American Depositary Share	-0.03%	-0.03%	+12.99%	+77.77%	+370.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LEGN Legend Biotech	3.6561 of 5 stars	4.5	3.0	0.0	0.0	3.2	1.7	0.6
RDY Dr. Reddy's Laboratories	2.7945 of 5 stars	2.5	4.0	1.7	0.0	2.2	0.0	1.9
SRPT Sarepta Therapeutics	4.743 of 5 stars	4.2	2.0	0.0	4.2	2.9	1.7	1.9
VRNA Verona Pharma PLC American Depositary Share	2.3103 of 5 stars	2.1	5.0	0.0	0.0	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LEGN Legend Biotech	2.91	Moderate Buy	$73.33	74.06% Upside
RDY Dr. Reddy's Laboratories	3.00	Buy	$16.95	15.27% Upside
SRPT Sarepta Therapeutics	2.44	Hold	$57.00	159.44% Upside
VRNA Verona Pharma PLC American Depositary Share	2.15	Hold	$109.00	4.03% Upside

Current Analyst Ratings Breakdown

Latest VRNA, LEGN, SRPT, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
7/17/2025	LEGN Legend Biotech	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/17/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
7/17/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $65.00
7/17/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$29.00 ➝ $32.00
7/17/2025	SRPT Sarepta Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$25.00 ➝ $23.00
7/17/2025	SRPT Sarepta Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
7/17/2025	SRPT Sarepta Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $35.00
7/14/2025	VRNA Verona Pharma PLC American Depositary Share	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$90.00 ➝ $107.00
7/10/2025	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$80.00 ➝ $81.00
7/10/2025	SRPT Sarepta Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $28.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LEGN Legend Biotech	$627.24M	12.34	N/A	N/A	$5.70 per share	7.39
RDY Dr. Reddy's Laboratories	$3.81B	3.22	$1.04 per share	14.15	$4.73 per share	3.11
SRPT Sarepta Therapeutics	$1.90B	1.14	$2.91 per share	7.55	$15.99 per share	1.37
VRNA Verona Pharma PLC American Depositary Share	$42.28M	210.97	N/A	N/A	$2.56 per share	40.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LEGN Legend Biotech	-$177.03M	-$0.59	N/A	N/A	N/A	-29.95%	-21.19%	-13.47%	8/8/2025 (Estimated)
RDY Dr. Reddy's Laboratories	$663M	$0.66	22.28	17.93	5.18	17.38%	17.98%	12.24%	7/25/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	2.01	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)
VRNA Verona Pharma PLC American Depositary Share	-$173.42M	-$2.00	N/A	3,492.67	N/A	N/A	-69.65%	-28.00%	8/6/2025 (Estimated)

Latest VRNA, LEGN, SRPT, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	LEGN Legend Biotech	-$0.18	N/A	N/A	N/A	$237.49 million	N/A
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	N/A	N/A	N/A	$530.66 million	N/A
8/6/2025	Q2 2025	VRNA Verona Pharma PLC American Depositary Share	$0.39	N/A	N/A	N/A	$68.24 million	N/A
7/25/2025	Q1 25/26	RDY Dr. Reddy's Laboratories	$0.19	N/A	N/A	N/A	$88.27 billion	N/A
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.40	-$0.07	+$0.33	-$0.27	$190.83 million	$195.05 million
5/9/2025	Q4 24/25	RDY Dr. Reddy's Laboratories	$0.20	$0.22	+$0.02	$0.22	$83.70 billion	$996.17 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million
4/29/2025	Q1 2025	VRNA Verona Pharma PLC American Depositary Share	-$0.22	$0.27	+$0.49	-$0.16	$41.47 million	$98.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.08	0.54%	N/A	12.12%	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma PLC American Depositary Share	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LEGN Legend Biotech	0.30	5.20	5.07
RDY Dr. Reddy's Laboratories	0.02	1.92	1.37
SRPT Sarepta Therapeutics	1.00	4.02	2.46
VRNA Verona Pharma PLC American Depositary Share	1.07	8.86	8.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LEGN Legend Biotech	70.89%
RDY Dr. Reddy's Laboratories	3.85%
SRPT Sarepta Therapeutics	86.68%
VRNA Verona Pharma PLC American Depositary Share	85.88%

Insider Ownership

Company	Insider Ownership
LEGN Legend Biotech	0.02%
RDY Dr. Reddy's Laboratories	2.00%
SRPT Sarepta Therapeutics	7.70%
VRNA Verona Pharma PLC American Depositary Share	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LEGN Legend Biotech	2,609	183.76 million	183.73 million	Optionable
RDY Dr. Reddy's Laboratories	27,811	834.90 million	818.20 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable
VRNA Verona Pharma PLC American Depositary Share	30	85.13 million	81.05 million	Optionable

VRNA, LEGN, SRPT, and RDY Headlines

Recent News About These Companies

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sees Unusually-High Trading Volume - Here's What Happened

July 16 at 2:18 PM | marketbeat.com

Weathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA Now

July 16 at 11:11 AM | zacks.com

Jacobson & Schmitt Advisors LLC Lowers Stock Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

July 16 at 10:12 AM | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given "Neutral" Rating at HC Wainwright

July 16 at 3:01 AM | americanbankingnews.com

HC Wainwright & Co. Downgrades Verona Pharma plc - Depositary Receipt () (VRNA)

July 15 at 11:46 PM | msn.com

What Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?

July 15 at 11:46 PM | msn.com

What Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?

July 15 at 1:01 PM | zacks.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)

July 14 at 7:07 PM | globenewswire.com

Pharmaceutical Stocks To Research - July 14th

July 14 at 2:47 PM | marketbeat.com

TimesSquare Capital Management LLC Acquires New Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

July 14 at 8:50 AM | marketbeat.com

HC Wainwright Reiterates "Neutral" Rating for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

July 14 at 8:45 AM | marketbeat.com

Rice Hall James & Associates LLC Has $52.25 Million Stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

July 14 at 6:34 AM | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Cut to "Hold" at BTIG Research

July 13, 2025 | americanbankingnews.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Cut to Hold at Roth Capital

July 13, 2025 | americanbankingnews.com

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

July 12, 2025 | businesswire.com

BTIG Downgrades Verona Pharma plc - Depositary Receipt () (VRNA)

July 12, 2025 | msn.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Cut to "Hold" at Wolfe Research

July 12, 2025 | marketbeat.com

Diversify Wealth Management LLC Acquires 3,572 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

July 12, 2025 | marketbeat.com

Alps Advisors Inc. Sells 5,993 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

July 12, 2025 | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Rating Lowered to Hold at Wells Fargo & Company

July 12, 2025 | americanbankingnews.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stock Rating Lowered by TD Cowen

July 12, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRNA, LEGN, SRPT, and RDY Company Descriptions

Legend Biotech NASDAQ:LEGN

$42.13 +2.38 (+5.99%)

Closing price 04:00 PM Eastern

Extended Trading

$42.42 +0.29 (+0.70%)

As of 07:57 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Dr. Reddy's Laboratories NYSE:RDY

$14.70 +0.09 (+0.64%)

Closing price 03:59 PM Eastern

Extended Trading

$14.73 +0.02 (+0.17%)

As of 05:31 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Sarepta Therapeutics NASDAQ:SRPT

$21.97 +3.59 (+19.53%)

Closing price 04:00 PM Eastern

Extended Trading

$22.02 +0.05 (+0.25%)

As of 07:59 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$104.78 +0.04 (+0.04%)

Closing price 04:00 PM Eastern

Extended Trading

$104.71 -0.07 (-0.07%)

As of 07:56 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time